跳至主要内容
临床试验/ITMCTR2100004619
ITMCTR2100004619招募中4 期

A Randomized Controlled Trial About the Efficacy and Safety of Naoxintong Capsule for Treating Chronic Stable Angina

The Second Clinical Medical College of Guangzhou University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • (1) A diagnosis of CHD and the provision of exact imaging information (coronary angiography or computed tomography coronary angiography confirmation of stenosis greater than 50% of at least one major branch of the coronary artery luminal diameter, or nuclear perfusion scan diagnosed as CAD). CCS classification of angina grade II;
  • (2) The onset of angina pectoris >= 3 months previous and the frequency of angina attack >= twice a week;
  • (3) Age between 35 and 75, regardless of gender;
  • (4) Signed informed consent by participants or surrogates.

排除标准

  • (1) Uncontrolled or mismanaged blood pressure and blood glucose. Severe cardiopulmonary insufficiency, or severe arrhythmia (rapid atrial fibrillation and flutter, paroxysmal ventricular tachycardia second degree and greater than a second degree atrioventricular (AV) block). Acute MI in the past 2 months, or has undergone coronary revascularization in the past 12 months.
  • (2) Renal dysfunction, male serum creatinine >2.5 mg/ dl (>220 µmol/L) or female serum creatinine >2.0 mg/ dl (>175 µmol/L). Serious liver disease (expression of aminotransferase (ALT) and aspartate aminotransferase (AST) of 1.5 times higher than the normal upper limit).
  • (3) Factors that precluded satisfactory interpretation of the electrocardiogram (ECG) (e.g. digoxin therapy, left bundle branch block, implanted with pacemaker, left ventricular hypertrophy, or electrolyte disturbance).
  • (4) Complications with a serious bone joint disease or other comorbidities that may interfere with ability to perform required ETT.
  • (5) Patients planning to undergo coronary revascularization during the study period.
  • (6) Patients who might be allergic or are known to be allergic to ingredients of the study drug.
  • (7) Pregnant, pregnancy planners or lactating women.
  • (8) Patients who are allergic to NXT capsule.
  • (9) Substance abuse, alcohol and drug dependence in the last 2 years.
  • (10) Patients who participated in other clinical drug trials within 1 month.

研究者

发起方
The Second Clinical Medical College of Guangzhou University of Chinese Medicine

相似试验